Which has stronger earnings & valuation, ADMA or NGNE?

ADMA Biologics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $510.17M 3.95 $146.93M $0.68 12.79 Neurogene $930K 510.87 -$90.35M -$4.55 N/A

Is ADMA or NGNE more profitable?

ADMA Biologics has a net margin of 32.43% compared to Neurogene's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.43% 39.98% 28.08% Neurogene N/A -37.88% -34.70%

Does the media favor ADMA or NGNE?

In the previous week, ADMA Biologics had 36 more articles in the media than Neurogene. MarketBeat recorded 37 mentions for ADMA Biologics and 1 mentions for Neurogene. ADMA Biologics' average media sentiment score of 0.06 beat Neurogene's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 2 Very Positive mention(s) 5 Positive mention(s) 28 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NGNE or STOK?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Stoke Therapeutics and 1 mentions for Neurogene. Stoke Therapeutics' average media sentiment score of 0.29 beat Neurogene's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, GENB or NGNE?

Generate Biomedicines has higher revenue and earnings than Neurogene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Generate Biomedicines $30.30M 68.67 N/A N/A N/A Neurogene $930K 510.87 -$90.35M -$4.55 N/A

Is GENB or NGNE more profitable?

Generate Biomedicines' return on equity of 0.00% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Neurogene N/A -37.88% -34.70%

Does the media refer more to GENB or NGNE?

In the previous week, Generate Biomedicines had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Neurogene. Generate Biomedicines' average media sentiment score of 0.00 equaled Neurogene'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NGNE or MESO?

Neurogene presently has a consensus price target of $84.83, suggesting a potential upside of 182.12%. Given Neurogene's stronger consensus rating and higher probable upside, research analysts clearly believe Neurogene is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has preferable earnings and valuation, NGNE or MESO?

Neurogene has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neurogene $930K 510.87 -$90.35M -$4.55 N/A Mesoblast $17.20M 117.04 -$102.14M -$0.54 N/A

Is NGNE or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Mesoblast N/A N/A N/A

Does the media favor NGNE or MESO?

In the previous week, Mesoblast had 2 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Mesoblast and 1 mentions for Neurogene. Mesoblast's average media sentiment score of 0.18 beat Neurogene's score of 0.00 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IOVA or NGNE?

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 1 mentions for Neurogene. Iovance Biotherapeutics' average media sentiment score of 0.75 beat Neurogene's score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neurogene (NGNE) Competitors

$30.07 -0.79 (-2.56%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$31.22 +1.15 (+3.84%)

As of 06/24/2026 06:12 PM Eastern

Compare

NGNE vs. ADMA, STOK, GENB, MESO, and IOVA

Should you buy Neurogene stock or one of its competitors? MarketBeat compares Neurogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurogene include ADMA Biologics (ADMA), Stoke Therapeutics (STOK), Generate Biomedicines (GENB), Mesoblast (MESO), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.

How does Neurogene compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Neurogene (NASDAQ:NGNE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

ADMA Biologics has a net margin of 32.43% compared to Neurogene's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Neurogene	N/A	-37.88%	-34.70%

ADMA Biologics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.95	$146.93M	$0.68	12.79
Neurogene	$930K	510.87	-$90.35M	-$4.55	N/A

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics currently has a consensus price target of $19.67, indicating a potential upside of 126.05%. Neurogene has a consensus price target of $84.83, indicating a potential upside of 182.12%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, ADMA Biologics had 36 more articles in the media than Neurogene. MarketBeat recorded 37 mentions for ADMA Biologics and 1 mentions for Neurogene. ADMA Biologics' average media sentiment score of 0.06 beat Neurogene's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	2 Very Positive mention(s)	5 Positive mention(s)	28 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Summary

ADMA Biologics beats Neurogene on 10 of the 16 factors compared between the two stocks.

How does Neurogene compare to Stoke Therapeutics?

Neurogene (NASDAQ:NGNE) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Stoke Therapeutics has higher revenue and earnings than Neurogene. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	510.87	-$90.35M	-$4.55	N/A
Stoke Therapeutics	$184.42M	10.27	-$6.89M	-$2.81	N/A

Neurogene currently has a consensus target price of $84.83, suggesting a potential upside of 182.12%. Stoke Therapeutics has a consensus target price of $41.83, suggesting a potential upside of 37.61%. Given Neurogene's stronger consensus rating and higher probable upside, equities analysts clearly believe Neurogene is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

52.4% of Neurogene shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neurogene has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 2 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Stoke Therapeutics and 1 mentions for Neurogene. Stoke Therapeutics' average media sentiment score of 0.29 beat Neurogene's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Neurogene's return on equity of -37.88% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Summary

Neurogene beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Neurogene compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Neurogene (NASDAQ:NGNE) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

52.4% of Neurogene shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Generate Biomedicines currently has a consensus target price of $25.40, indicating a potential upside of 56.50%. Neurogene has a consensus target price of $84.83, indicating a potential upside of 182.12%. Given Neurogene's stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Generate Biomedicines had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Neurogene. Generate Biomedicines' average media sentiment score of 0.00 equaled Neurogene'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines' return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Neurogene	N/A	-37.88%	-34.70%

Generate Biomedicines has higher revenue and earnings than Neurogene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	68.67	N/A	N/A	N/A
Neurogene	$930K	510.87	-$90.35M	-$4.55	N/A

Summary

Neurogene beats Generate Biomedicines on 6 of the 11 factors compared between the two stocks.

How does Neurogene compare to Mesoblast?

Neurogene (NASDAQ:NGNE) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Mesoblast had 2 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Mesoblast and 1 mentions for Neurogene. Mesoblast's average media sentiment score of 0.18 beat Neurogene's score of 0.00 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neurogene presently has a consensus price target of $84.83, suggesting a potential upside of 182.12%. Given Neurogene's stronger consensus rating and higher probable upside, research analysts clearly believe Neurogene is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Neurogene has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	510.87	-$90.35M	-$4.55	N/A
Mesoblast	$17.20M	117.04	-$102.14M	-$0.54	N/A

Mesoblast's return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Mesoblast	N/A	N/A	N/A

Neurogene has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Summary

Neurogene and Mesoblast tied by winning 8 of the 16 factors compared between the two stocks.

How does Neurogene compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Neurogene has lower revenue, but higher earnings than Iovance Biotherapeutics. Neurogene is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	7.19	-$390.98M	-$0.95	N/A
Neurogene	$930K	510.87	-$90.35M	-$4.55	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Neurogene's return on equity of -37.88% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Neurogene	N/A	-37.88%	-34.70%

Iovance Biotherapeutics presently has a consensus target price of $8.43, suggesting a potential upside of 98.51%. Neurogene has a consensus target price of $84.83, suggesting a potential upside of 182.12%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Iovance Biotherapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 1 mentions for Neurogene. Iovance Biotherapeutics' average media sentiment score of 0.75 beat Neurogene's score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neurogene beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$487.65M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-6.61	20.50	25.37	23.95
Price / Sales	510.87	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	1.76	8.26	10.76	6.41
Net Income	-$90.35M	$23.91M	$3.56B	$337.14M
7 Day Performance	-4.63%	2.12%	0.99%	-1.06%
1 Month Performance	8.52%	2.40%	0.79%	0.49%
1 Year Performance	78.14%	57.09%	30.25%	28.43%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	2.5765 of 5 stars	$30.07 -2.6%	$84.83 +182.1%	+74.8%	$487.65M	$930K	N/A	90
ADMA ADMA Biologics	4.4968 of 5 stars	$8.65 +0.9%	$19.67 +127.5%	-51.3%	$2.01B	$509.86M	12.75	530	Trending News
STOK Stoke Therapeutics	2.501 of 5 stars	$32.16 +3.8%	$41.83 +30.1%	+164.1%	$2.00B	$32.08M	N/A	100
GENB Generate Biomedicines	N/A	$15.50 -2.4%	$25.40 +63.8%	N/A	$1.99B	$30.30M	N/A	312
MESO Mesoblast	1.2321 of 5 stars	$15.33 -1.1%	N/A	+48.8%	$1.99B	$65.38M	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. ADMA, STOK, GENB, MESO, and IOVA

How does Neurogene compare to ADMA Biologics?

Summary

How does Neurogene compare to Stoke Therapeutics?

Summary

How does Neurogene compare to Generate Biomedicines?

Summary

How does Neurogene compare to Mesoblast?

Summary

How does Neurogene compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. ADMA, STOK, GENB, MESO, and IOVA

How does Neurogene compare to ADMA Biologics?

Is ADMA or NGNE more profitable?

Which has stronger earnings & valuation, ADMA or NGNE?

Do institutionals and insiders believe in ADMA or NGNE?

Do analysts rate ADMA or NGNE?

Does the media favor ADMA or NGNE?

Which has more risk and volatility, ADMA or NGNE?

Summary

How does Neurogene compare to Stoke Therapeutics?

Which has preferable valuation & earnings, NGNE or STOK?

Do analysts recommend NGNE or STOK?

Do institutionals & insiders hold more shares of NGNE or STOK?

Which has more volatility and risk, NGNE or STOK?

Does the media refer more to NGNE or STOK?

Is NGNE or STOK more profitable?

Summary

How does Neurogene compare to Generate Biomedicines?

Do institutionals & insiders believe in GENB or NGNE?

Do analysts rate GENB or NGNE?

Does the media refer more to GENB or NGNE?

Is GENB or NGNE more profitable?

Which has stronger earnings and valuation, GENB or NGNE?

Summary

How does Neurogene compare to Mesoblast?

Does the media favor NGNE or MESO?

Do insiders and institutionals have more ownership in NGNE or MESO?

Do analysts prefer NGNE or MESO?

Which has preferable earnings and valuation, NGNE or MESO?

Is NGNE or MESO more profitable?

Which has more volatility & risk, NGNE or MESO?

Summary

How does Neurogene compare to Iovance Biotherapeutics?

Which has higher earnings & valuation, IOVA or NGNE?

Do institutionals & insiders have more ownership in IOVA or NGNE?

Is IOVA or NGNE more profitable?

Do analysts prefer IOVA or NGNE?

Which has more risk and volatility, IOVA or NGNE?

Does the media prefer IOVA or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools